Zevra Therapeutics (ZVRA) Set to Post Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is anticipated to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.14 per share and revenue of $37.08 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The company had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. On average, analysts expect Zevra Therapeutics to post $0.72 EPS for the current fiscal year and $0.84 EPS for the next fiscal year.

Zevra Therapeutics Stock Down 2.9%

NASDAQ:ZVRA opened at $9.53 on Tuesday. The stock’s fifty day moving average is $11.30 and its two-hundred day moving average is $10.70. Zevra Therapeutics has a 52 week low of $8.01 and a 52 week high of $15.03. The stock has a market capitalization of $565.89 million, a price-to-earnings ratio of 6.21 and a beta of 0.98.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 20,000 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the transaction, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on ZVRA. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Citizens Jmp raised their price objective on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average target price of $27.14.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.